FDA Approves HERCEPTIN — Genentech, Inc.

# FDA Approves Genentech's Herceptin for HER2-Positive Breast Cancer Genentech's HERCEPTIN (trastuzumab), the first monoclonal antibody approved for cancer treatment, has received FDA clearance, opening a significant new market segment for targeted immunotherapy and positioning the company as a leader in precision oncology. The approval is expected to transform treatment outcomes for HER2-positive breast cancer patients while establishing a substantial revenue opportunity for Genentech in the growing biologic therapeutics market.